Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer
Full text links

Actions

Share

.2015 Oct;38(10):909-19.
doi: 10.1007/s40264-015-0319-3.

Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis

Affiliations

Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis

Patrick Imfeld et al. Drug Saf.2015 Oct.

Abstract

Introduction: Previous observational studies have associated benzodiazepine use with an increased risk of dementia. However, limitations in the study methods leave questions unanswered regarding the interpretation of the findings.

Methods: A case-control analysis was conducted using data from the UK-based Clinical Practice Research Datalink (CPRD). A total of 26,459 patients aged ≥65 years with newly diagnosed Alzheimer's disease (AD) or vascular dementia (VaD) between 1998 and 2013 were identified and matched 1:1 to dementia-free controls on age, sex, calendar time, general practice, and number of years of recorded history. Adjusted odds ratios (aORs) were calculated with 95% confidence intervals (CIs) of developing AD or VaD in relation to previous benzodiazepine use, stratified by duration and benzodiazepine type.

Results: The aOR (95% CI) of developing AD for those who started benzodiazepines <1 year before diagnosis was 2.20 (1.91-2.53), and fell to the null for those who started between 2 and <3 years before [aOR 0.99 (0.84-1.17)]. The aOR (95% CI) of developing VaD for those who started benzodiazepines <1 year before diagnosis was 3.30 (2.78-3.92), and fell close to the null for those who started between 3 and <4 years before [aOR 1.16 (0.96-1.40)]. After accounting for benzodiazepine use initiated during this prodromal phase, long-term use of benzodiazepines was not associated with an increased risk of developing AD [aOR 0.69 (0.57-0.85)] or VaD [aOR 1.11 (0.85-1.45)].

Conclusion: After taking a prodromal phase into consideration, benzodiazepine use was not associated with an increased risk of developing AD or VaD.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Epidemiol Community Health. 2012 Oct;66(10):869-73 - PubMed
    1. J Clin Epidemiol. 2002 Mar;55(3):314-8 - PubMed
    1. Lancet. 2000 Nov 11;356(9242):1627-31 - PubMed
    1. PLoS One. 2012;7(11):e49113 - PubMed
    1. Curr Opin Psychiatry. 2014 May;27(3):230-5 - PubMed

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
Springer full text link Springer
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp